STERIS director Carestio proposes 1,374-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
STERIS plc (STE) officer and director Daniel A. Carestio reported a proposed sale of 1,374 ordinary shares, with an aggregate market value of 291,288.00 and an approximate sale date of June 5, 2026. The shares were acquired on June 2, 2026, through a restricted stock lapse as equity compensation. The securities information lists 97,602,485 shares or other units outstanding. The Rule 10b5-1 field lists June 6, 2024, as the plan adoption or instruction date. Carestio’s past-three-month sales table lists 3,054 shares sold on June 4, 2026, for gross proceeds of 655,511.00.
Key Figures
Key Terms
Restricted Stock Lapse financial
Equity Compensation financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Daniel A. Carestio sell in the three months before the STE notice?
What Rule 10b5-1 date is listed for the STE sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.